LYEL
Lyell Immunopharma, Inc.
There isn't enough reported data to score LYEL yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LYEL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
LYEL's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LYEL PE Valuation
LYEL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LYEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect LYEL's revenue to grow, with its earnings and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LYEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.32 | +$10.70 |
| Q2 2026 | -$12.59 | +$11.70 |
| Q1 2026 | -$13.56 | +$11.44 |
| Q4 2025 | -$16.06 | +$10.14 |
| Q3 2025 | -$23.02 | -$7.22 |
| Q2 2025 | -$24.29 | -$7.89 |
| Q1 2025 | -$25.00 | -$7.00 |
| Q4 2024 | -$26.20 | -$7.60 |
LYEL is still losing money, but far less than before: $12.32 per share over the past year, against $26.20 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LYEL on earnings quality, reporting a profit while its opponent remains loss making.
LYEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3K | -80% |
| Q2 2026 | $4K | -50% |
| Q1 2026 | $2K | -71% |
| Q4 2025 | $6K | -45% |
| Q3 2025 | $15K | -56% |
| Q2 2025 | $8K | -38% |
| Q1 2025 | $7K | +133% |
| Q4 2024 | $11K | -15% |
LYEL's revenue has slid since its 2022 peak: $3,000 last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1609833% | -1361480 points |
| Q2 2026 | -1183425% | -594175 points |
| Q1 2026 | -2213050% | -1393521 points |
| Q4 2025 | -2127400% | -298791 points |
| Q3 2025 | -248353% | -99809 points |
| Q2 2025 | -589250% | -192881 points |
| Q1 2025 | -819529% | +1032971 points |
| Q4 2024 | -1828609% | -1370855 points |
LYEL's operating margin was −1609833% last quarter, down 1361480 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LYEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LYEL on profitability, with a higher operating margin.
LYEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.6M | -$6M |
| Q2 2026 | -$34.2M | +$448K |
| Q1 2026 | -$38.6M | +$16.4M |
| Q4 2025 | -$32.6M | +$14.7M |
| Q3 2025 | -$28.6M | +$6.5M |
| Q2 2025 | -$34.6M | +$3.8M |
| Q1 2025 | -$55M | -$12.9M |
| Q4 2024 | -$47.3M | -$6.6M |
LYEL has burned cash in almost every quarter: −$140M over the past year, against −$166M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LYEL on cash generation, producing positive trailing cash flow while its opponent burns cash.
LYEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +1.1M shares |
| 1 year | +65% | +9.6M shares |
| 3 years | +95% | +11.9M shares |
| 5 years | +105% | +12.5M shares |
LYEL has 24M diluted shares, up 65% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $11.8M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over LYEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LYEL Net Leverage
LYEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LYEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 65.6 | Neutral |
LYEL's weekly RSI is 55 (neutral) and its Stochastic is 66 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LYEL PE vs Healthcare Sector
LYEL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LYEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 44% above |
| 20 week MA | $12.5 | 25% above |
| 50 week MA | $18.3 | 14% below |
| 100 week MA | $15.3 | 2.2% above |
| 200 week MA | $28.4 | 45% below |
LYEL's trend is mixed: it's above three of its five weekly moving averages, and 45% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LYEL on trend strength, trading above more of its moving averages.
LYEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $324.0 | $164.2 | -49% |
| 2022 | $164.2 | $61.0 | -63% |
| 2023 | $61.0 | $38.8 | -36% |
| 2024 | $38.8 | $13.0 | -66% |
| 2025 | $13.0 | $35.1 | +170% |
| 2026 YTD | $35.1 | $15.6 | -55% |
LYEL's yearly returns have swung widely, from +170% in 2025 to −66% in 2024. It's down 55% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LYEL on returns for 2026, with the stronger performance.